Emerging Topics in Heart Failure: Interventional Heart Failure Therapies

João Manoel Rossi Neto,1,2,3 Dirceu Rodrigues de Almeida,2,3 Fernando Antibus Atik,4,5 Monica Samuel Avila,4,5 Marceily Gimenes Bonatto3

Instituto Dante Pazzanese de Cardiologia,1 São Paulo, SP – Brazil
Universidade Federal de São Paulo 2 São Paulo, SP – Brazil
Universidade de Brasília,3 Brasília, DF – Brazil
Instituto do Coração do Hospital das Clínicas da Universidade de São Paulo,4 São Paulo, SP – Brazil
Hospital Santa Casa de Misericórdia de Curitiba,5 Curitiba, PR - Brazil

Research letter related to Heart Failure Summit Brazil 2020 / Heart Failure Department - Brazilian Society of Cardiology

Treatment of Secondary Mitral Regurgitation

Before considering percutaneous treatment of mitral regurgitation (MR) for patients with heart failure (HF) with reduced ejection fraction (HFrEF) and severe MR,1 we recommend that guideline-directed medical therapy be optimized, including cardiac resynchronization therapy and revascularization, where appropriate. The use of the edge-to-edge device could benefit patients with moderately severe or severe secondary MR (effective regurgitant orifice area [EROA] ≥ 30 mm² and/or regurgitant volume > 45 mL) with a left ventricular ejection fraction (LVEF) of 20 to 50%, left ventricular (LV) end-systolic diameter < 7.0 cm, and persistent symptoms despite maximized evidence-based medical therapy, with the participation of an experienced multidisciplinary team in the evaluation and treatment of HF and MR.2

The COAPT trial included patients with more severe MR and less advanced LV disease (dilatation/dysfunction) compared to patients of the MITRA-FR trial, creating the concept of disproportionate MR (Table 1).

When to Indicate an Implantable Cardioverter Defibrillator (ICD) in Face of New Medications in HFrEF?

Ischemic Cardiomyopathy

The randomized MADIT II and SCD-HeFT trials,3,4 conducted more than 15 years ago, indicated the validation of ICDs for the primary prevention of sudden cardiac death (SCD) in patients with ischemic cardiomyopathy with an ejection fraction ≤ 35% in New York Heart Association (NYHA) class II or III after optimization of medical therapy, after at least 40 days of any myocardial revascularization procedure, without severe comorbidities and with good 1-year life expectancy. These trials were conducted at a time when pharmacologic treatment was far less than desirable in terms of doses. Currently, medications can promote a substantial reduction in the annual rate of SCD.3,6

Nonischemic Cardiomyopathy

Small randomized trials (CAT, AMIOVIRT, and DEFINITE), conducted more than 10 years ago, were unable to demonstrate a reduction in mortality with the use of ICDs for primary prevention of SCD in nonischemic cardiomyopathy.5 Recently, the DANISH trial,7 with a robust sample of properly treated patients, also demonstrated that ICDs did not reduce total mortality or cardiovascular death in this population. We should consider greater risk stratification in these patients by incorporating magnetic resonance imaging quantification of fibrosis, which has shown to be associated with cardiovascular death and SCD in patients with nonischemic cardiomyopathy.8

Pulmonary-vein Isolation for the Treatment of Atrial Fibrillation (AF) in Patients with HFrEF

AF ablation in patients with HF provides greater benefit than the use of antiarrhythmic medications due to higher sinus rhythm maintenance rate, improved functional capacity and quality of life, improved NYHA class, longer 6-minute-walk distance, improved peak VO₂,9 reduced biomarker (brain natriuretic peptide [BNP]) levels, increased ejection fraction,9,10 and reduced HF hospitalization, HF death or hospitalization, and death from any cause.9,11 However, the success rate ranges from 60 to 80% at 1 year, when structural heart disease is a risk factor for recurrence.12 Pulmonary-vein isolation can be achieved by radiofrequency or cryoablation, and these techniques can be combined with ablation of other substrates. Benefits include symptom control in patients with paroxysmal/persistent AF and the promotion of reverse remodeling in patients with ventricular dysfunction due to AF-induced tachycardiomyopathy, regardless of symptoms.

New Forms of Cardiac Pacing in HF

Ventricular pacing through the native His-Purkinje conduction system may be an option for patients with pacemaker indication, given the deleterious effects of isolated right ventricular (RV) pacing in patients with HF.13
Small trials suggest that His bundle pacing may result in a decrease in the incidence of cardiomyopathy, reduction in the combined endpoint of hospitalization or death, and improvement in LV dimensions and HF symptoms compared to isolated RV pacing. The American guideline for the management of bradycardia recommends His bundle pacing or cardiac resynchronization therapy for patients with ventricular dysfunction who have atrioventricular block with an indication for permanent pacemaker instead of isolated RV pacing. Compared to cardiac resynchronization therapy, His bundle pacing had an equivalent effect, with a significant reduction in QRS duration and improvement in LVEF, HF symptoms, and quality of life. His bundle pacing was also tested in patients with HFrEF and right bundle branch block, leading to increased LVEF and narrowing of QRS duration.

Percutaneous Treatment of Tricuspid Regurgitation in HF

The advent of percutaneous treatment of functional tricuspid regurgitation is attractive in selected patients at high surgical risk, for an expected improvement of symptoms. Patients who may benefit from this treatment include those with HF refractory to optimized medical therapy or with early signs of RV dysfunction, who are considered at high risk for conventional cardiac surgery or inoperable. Devices are divided into annuloplasty systems, tricuspid valve repair systems, and prosthetic valves for vena cava stenting. Although safety and efficacy clinical trials appear to be promising, the available evidence is based on single-center observational studies or registries. Therefore, more robust evidence is needed before we can confidently indicate any treatment.

List of Participants of the Heart Failure Summit Brazil. 2020 / Heart Failure Department - Brazilian Society of Cardiology


Author contributions

Conception and design of the research, Acquisition of data, Analysis and interpretation of the data, Statistical analysis, Obtaining financing, Writing of the manuscript and Critical revision of the manuscript for intellectual content: Rossi Neto JM, Almeida DR, Atik FA, Avila MS, Bonatto MG.

Table 1 – Comparison of the characteristics and results of the COAPT and MITRA-FR trials

<table>
<thead>
<tr>
<th></th>
<th>MITRA-FR</th>
<th>COAPT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of patients</td>
<td>304</td>
<td>614</td>
</tr>
<tr>
<td>Medical therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 moderate to severe (3+) IMR</td>
<td>EROA &gt; 20 mm² and/or RV &gt; 30 mL</td>
<td>EROA &gt; 30 mm² and/or RV &gt; 45 mL</td>
</tr>
<tr>
<td>LVESD, mm (LV size)</td>
<td>Without limit</td>
<td>&lt;70 upon inclusion</td>
</tr>
<tr>
<td>NYHA class &gt; II, %</td>
<td>67.0</td>
<td>60.4</td>
</tr>
<tr>
<td>Hospital in previous years, %</td>
<td>100</td>
<td>57.1</td>
</tr>
<tr>
<td>EROA, mm2</td>
<td>31 ± 10</td>
<td>41 ± 15</td>
</tr>
<tr>
<td>Severe (EROA ≥ 40 mm2), %</td>
<td>16</td>
<td>41</td>
</tr>
<tr>
<td>iLVEDV, mL/m2</td>
<td>135 ± 35</td>
<td>101 ± 34</td>
</tr>
<tr>
<td>1-year mortality (IvsC), %</td>
<td>24.2 ± 22.4</td>
<td>19.1 ± 23.2 (p &lt; 0.001)</td>
</tr>
<tr>
<td>1-year HF hospitalization (IvsC), %</td>
<td>48.7 ± 47.4</td>
<td>35.8 ± 67.9 (p &lt; 0.001) Primary objective</td>
</tr>
<tr>
<td>Annual mortality/ HF hospitalization (IvsC), %</td>
<td>54.6 vs 51.3 (p=0.53) Primary objective</td>
<td>33.9 vs 46.5 (p &lt; 0.001)</td>
</tr>
</tbody>
</table>

iMR: ischemic mitral regurgitation; EROA: effective regurgitant orifice area; RV: regurgitant volume; LVESD: left ventricular end-systolic diameter; NYHA: New York Heart Association; iLVEDV: indexed left ventricular end-diastolic volume; IvsC: Invasive vs Control; HF: heart failure.
Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Sources of Funding

There were no external funding sources for this study.

References


